AtaiBeckley (ATAI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
CEO welcomed shareholders and outlined the meeting's legal and procedural framework.
Board members, executive team, advisors, and independent auditor were introduced.
Gratitude was expressed to shareholders for their ongoing support.
Strategic initiatives and plans
Recent strategic combination and U.S. re-domiciliation were highlighted as pivotal moves.
Emphasis on capital position, pipeline breadth, and upcoming clinical catalysts.
Focus on advancing next-generation psychedelic therapies for mental health.
Shareholder proposals
Two proposals were presented: election of three Class 1 directors and ratification of the independent auditor.
Board recommended voting in favor of both proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from AtaiBeckley
- BPL-003 enters phase III as part of a robust, innovative neuropsychiatric pipeline.ATAI
7th Annual HCW Neuro Perspectives Hybrid Conference15 Jun 2026 - BPL-003 enters phase III for depression, with top-line data expected in early 2029.ATAI
Jefferies Global Healthcare Conference 20263 Jun 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance in place.ATAI
Proxy filing18 May 2026 - Election of directors and auditor ratification are up for vote at the June 2026 annual meeting.ATAI
Proxy filing18 May 2026 - Q1 2026 net loss rose to $29.8M on higher R&D and G&A costs; cash runway extends into 2029.ATAI
Q1 202618 May 2026 - Phase III trials advance BPL-003 in TRD and EMP-01 shows rapid efficacy in social anxiety disorder.ATAI
TD Cowen 46th Annual Health Care Conference18 May 2026 - BPL-003’s rapid, durable efficacy and convenience drive its advancement to Phase 3 in TRD.ATAI
Investor Day 20268 May 2026 - Accelerated regulatory pathways and robust clinical data are driving psychedelics toward market launch.ATAI
Needham Virtual Psychedelics Forum28 Apr 2026 - BPL-003 advances to phase III for TRD, aiming for rapid, durable relief and Q1 2029 results.ATAI
25th Annual Needham Virtual Healthcare Conference16 Apr 2026